NCT04541082View on ClinicalTrials.gov

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

PHASE1RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Central Nervous System NeoplasmsGlioblastomaGliosarcoma, AdultAnaplastic OligodendrogliomaAnaplastic AstrocytomaPilocytic AstrocytomaOligodendrogliomaGliomatosis CerebriPleomorphic XanthoastrocytomaAnaplastic Pleomorphic XanthoastrocytomaDiffuse Midline Glioma, H3 K27M-MutantEpendymomaEpendymoma, AnaplasticMedulloblastomaTeratoid Rhabdoid TumorNeuroectodermal Tumors, PrimitiveNeuroectodermal TumorsAnaplastic MeningiomaAtypical MeningiomaChoroid Plexus NeoplasmsPineal TumorDiffuse AstrocytomaGlial Tumor
Interventions
DRUG

ONC206

ONC206 is a member of the imipridone class of anti-cancer small molecules that share a unique tri-heterocyclic core chemical structure and target G protein-coupled receptors.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health, Bethesda

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Jazz Pharmaceuticals

INDUSTRY